Nuvalent Past Earnings Performance

Past criteria checks 0/6

Nuvalent's earnings have been declining at an average annual rate of -49.6%, while the Biotechs industry saw earnings growing at 19.3% annually.

Key information

-49.6%

Earnings growth rate

32.4%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth raten/a
Return on equity-20.0%
Net Marginn/a
Last Earnings Update30 Sep 2024

Recent past performance updates

No updates

Recent updates

We're Hopeful That Nuvalent (NASDAQ:NUVL) Will Use Its Cash Wisely

Nov 18
We're Hopeful That Nuvalent (NASDAQ:NUVL) Will Use Its Cash Wisely

Nuvalent: Promising Data Keeps Validating Pipeline And Platform

Sep 23

Nuvalent: Likely Approvals Coming Up Do Not Justify This Valuation

Sep 17

Nuvalent (NASDAQ:NUVL) Is In A Strong Position To Grow Its Business

Aug 05
Nuvalent (NASDAQ:NUVL) Is In A Strong Position To Grow Its Business

Nuvalent: Making Precise Progress In Its Oncology Pipeline

Jun 24

Nuvalent: NVL-655 Could Bring Blockbuster Potential

Jun 14

Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Apr 22
Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Nuvalent: Pivotal NSCLC Programs Progressing With Additional Data In 2024

Feb 26

Is Nuvalent, Inc. (NASDAQ:NUVL) Trading At A 36% Discount?

Jan 07
Is Nuvalent, Inc. (NASDAQ:NUVL) Trading At A 36% Discount?

Companies Like Nuvalent (NASDAQ:NUVL) Can Afford To Invest In Growth

Sep 23
Companies Like Nuvalent (NASDAQ:NUVL) Can Afford To Invest In Growth

Here's Why We're Not At All Concerned With Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Jun 10
Here's Why We're Not At All Concerned With Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

We're Interested To See How Nuvalent (NASDAQ:NUVL) Uses Its Cash Hoard To Grow

Feb 24
We're Interested To See How Nuvalent (NASDAQ:NUVL) Uses Its Cash Hoard To Grow

Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Sep 13
Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Nuvalent GAAP EPS of -$0.38 beats by $0.03

Aug 10

Here's Why We're Not At All Concerned With Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

May 28
Here's Why We're Not At All Concerned With Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

We're Hopeful That Nuvalent (NASDAQ:NUVL) Will Use Its Cash Wisely

Oct 29
We're Hopeful That Nuvalent (NASDAQ:NUVL) Will Use Its Cash Wisely

Revenue & Expenses Breakdown

How Nuvalent makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:NUVL Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-22457184
30 Jun 240-17450153
31 Mar 240-14642130
31 Dec 230-12636113
30 Sep 230-11432101
30 Jun 230-1002886
31 Mar 230-892573
31 Dec 220-822264
30 Sep 220-732054
30 Jun 220-661849
31 Mar 220-571543
31 Dec 210-461036
30 Sep 210-36727
30 Jun 210-28422
31 Mar 210-27218
31 Dec 200-15215

Quality Earnings: NUVL is currently unprofitable.

Growing Profit Margin: NUVL is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: NUVL is unprofitable, and losses have increased over the past 5 years at a rate of 49.6% per year.

Accelerating Growth: Unable to compare NUVL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NUVL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: NUVL has a negative Return on Equity (-20.01%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies